Quick Takeaways
- This page summarizes Rachel McMinn's Form 4 filing for Neurogene Inc. (NGNE).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 30 Mar 2026, 17:38.
Rachel McMinn - 26 Mar 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)
- Signature
- /s/ Donna M. Cochener, as attorney-in-fact for Rachel McMinn
- Issuer symbol
- NGNE
- Transactions as of
- 26 Mar 2026
- Net transactions value
- -$73,995
- Form type
- 4
- Filing time
- 30 Mar 2026, 17:38:25 UTC
- Previous filing
- 24 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Rachel McMinn filed Form 4 for Neurogene Inc. (NGNE) on 30 Mar 2026."
What Changed
- Previous filing in this sequence was filed on 24 Feb 2026.
- Current net transaction value: -$73,995.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| McMinn Rachel | Chief Executive Officer, Director | C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK | /s/ Donna M. Cochener, as attorney-in-fact for Rachel McMinn | 30 Mar 2026 | 0001606302 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NGNE | Common Stock | Sale | $73,995 | -3,352 | -0.25% | $22.07 | 1,344,307 | 26 Mar 2026 | Direct | F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. |